Member Info for Joshholdforgold

Two joint accounts with 80,000 comments. You seriously need to get some sunlight.

Our government has chosen to buy more cheap Chinese crap rather than support (superior) British business.

Bull****.

Thanks RB - useful to know.

Rightback - could you explain what you mean by T3 traders pay up? Thanks in advance!

Ncyt, AVCT and Val have all done it too.

Are you lost hun?

To more seriously rebut Jolly’s ‘concerns’ for the benefit of potential investors:

ABDX have spent a significant proportion of their funds raised in their IPO to build two large capacity world class diagnostic manufacturing centres.

They are now out negotiating with the likes of avacta and I’m sure several others to fill their manufacturing capacity.

It is completely to be expected that more was spent than earned while the facilities were being built!

Jolly spectator - I’ll make you a gentleman’s bet. If we drop below 20p or have a placement before Xmas I’ll give £100 to charity? If not you do the same? Deal?

https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2019

These are the 15 biggest single drug deals of 2019.

Clearly shows £5-10bn is completely possible if we produce a best in class P3 data set.

I do not think a placement is likely. From memory there was £6m left in the last results.

I am confident that the tie up with avacta will see 100% return from these values. Not only will that ensure the share price recovers but that abdx will become a profitable company.

We have had 2 parts to our phase 2 trials. The first, in hospitalised patients read out in august, was fantastic and saw 500% gains on SP.
The second, was given at home to high risk patients. That share price crash was a response to the home trial results. They were not necessarily bad but a small sample size and not enough people progressing to severe disease in either the placebo or the treatment cohorts meant the data was not statistically significant.
Many felt that had it been statistic significant, we would have applied for emergency approval there and then.

Thanks Trek - everyday’s a school day.

Trek - I think poly are still buying.

# Trades 1,099
Vol. Sold 1,800,608
Sold Value £3m
Vol. Bought 1,766,823
Bought Value £3m

The only justification for the rise is a big buy order bench filled and not yet published.

As in last P3 patient recruited.

A2 progression?
Last patient recruited?

That was £50 a share if I remember correctly?

Silverbackmerch - my answer is exactly the same as yours except I’m 31!

Vol. Sold 1,313,700
Vol. Bought 1,098,196

This means that a large buy order must be being worked through. To see an 8% rise I imagine there must have been £400k-500k buy not yet published.
It surely must be polygon.

Interesting reply from BioSure Sales team. I received this after making an approach asking about purchasing tests for the employees of my company.

Key information:

1. BioSure are Selling Abc - Antibody tests as well as their own.

2. A saliva based CE marked antigen test is launching in October! Who will be manufacturing these....... 99% us.

3. Antibody tests can be bought now! Money is already trickling in.

ATB

Josh

Hi Josh

Thank you so much for getting in touch with BioSure.

We have a wealth of expertise and are working across a wide range of market sectors to provide solutions - a quick snapshot:

BioSure’s tests offers a unique proposition –
All tests are fully developed and manufactured in the UK (not repackaged Chinese tests)
All tests have been independently validated for their accuracy and provide results in real time
We are able to provide a full workplace testing package, including staff
BioSure tests can be provided with our app, to securely capture results and provide anonymised reporting to help keep your workforce COVID-19 safe
BioSure has a long and established history of providing diagnostic devices across the global market, including healthcare, the NHS, retail pharmacies, and direct to consumers

BioSURE COVID-19 IgG Antibody Self Test
Blood - the test requires 2.5µl (a fraction of a drop) of blood from a finger prick sample
The test detects IgG - it will detect the immune response to having the COVID-19 vaccine/, so you know if immunisation has been successful
Detects antibodies post infection
This test is CE marked specifically as a Self Test
Currently available

KnowNow COVID-19 Antigen Test:
Antigen tests detect people who currently have infection
Saliva – the test requires a saliva sample, no invasive nasopharyngeal or tonsil swabbing
Infectivity – the test works differently to any other antigen lateral flow test and detects the spike protein of the virus (as opposed to nucleocapsid protein) which is only present on live virus and therefore will only detect people who are currently infectious
Current data evidences 100% specificity (the number of times the test will correctly identify true negatives, ie no false positives) and has shown a level of detection down to 500 pfu/ml (which means it may actually detect someone the day before they become infectious)
Results in 15 minutes
The test is CE marked
Launching in October

AbC Antibody test
Antibody tests detect people who have had the virus
Blood - the tests require 5µl (a fraction of a drop) of blood from a finger prick sample
The ABC antibody test detects IgG - it will detect the immune response to having the COVID-19 vaccine, so you know if immunisation has been successful
This test is CE marked
Currently available

The KnowNow and AbC tests are for professional use - training can be provided by BioSure should this be required.

Please let me know which test would be most suited to your needs to I can send you further information.

Kind regards,
Julie